YOSEMITE, RHINE (2022): 두 판 사이의 차이

YOSEMITE, RHINE (2022) (원본 보기)

20 바이트 제거됨 , 2023년 10월 26일 (목)

잔글

편집 요약 없음

편집

13,127

번

@@ 1번째 줄: / 1번째 줄: @@
 {{논문
-|1=Efficacy, durability, and safety of intravitreal faricimab w extended dosing up to every 16w in patients w DME (YOSEMITE and RHINE) : 2 randomised, double-masked, P3, trials<ref>Wykoff CC et al; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab w extended dosing up to every 16w in patients w DME (YOSEMITE and RHINE) : 2 randomised, double-masked, P3 trials. ''Lancet''. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. PMID: 35085503.</ref>
+|1=Efficacy, durability, and safety of intravitreal faricimab w extended dosing up to every 16w in patients w DME (YOSEMITE and RHINE) : 2 randomised, double-masked, P3, trials<ref>Wykoff CC et al; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab w extended dosing up to every 16w in patients w DME (YOSEMITE and RHINE) : 2 randomised, double-masked, P3 trials. ''Lancet''. 2022 Feb 19;399(10326):741-755. [https://pubmed.ncbi.nlm.nih.gov/35085503 연결]</ref>
 |2=[[당뇨 황반부종]]에 대해 최대 16주마다 연장 투여하는 유리체강내 파리시맙의 효과, 지속성 및 안정성 (YOSEMITE, RHINE) : 두 무작위, 이중 맹검, 3상 임상 시험
 |3=Lancet